Clinicopathological and prognostic outcomes of endometriosis-associated ovarian cancer

Esra Keleş, Sahra Sultan Kara, Sadun Sucu
In: Ağrı Tıp Fakültesi Dergisi · 2025 · vol. 3(3) , pp. 102–106 · doi:10.61845/agrimedical.1674787 · W4415666315
article OA: bronze CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Endometriosis-associated ovarian cancer cases presented in younger patients at earlier FIGO stages with higher CA 19-9 levels, but showed no significant differences in recurrence rates or survival outcomes compared to non-endometriosis-associated cases.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 ⓘ

The paper examines clinicopathological features and prognostic outcomes of endometriosis-associated ovarian cancer, synthesizing information on how these cancers present and what survival or other outcome patterns are reported in relation to endometriosis involvement. It uses a study-design typical of clinical/clinicopathological outcome research, focusing on patient characteristics and prognostic endpoints rather than mechanistic experiments. A key limitation is that, as indicated by the framing and context of the topic, prognostic comparisons are potentially constrained by heterogeneity across studies and by limitations inherent in retrospective clinical datasets and varied classification of ovarian tumors. This paper is centrally about endometriosis—specifically, it focuses on ovarian cancer occurring in association with endometriosis and its clinicopathological and prognostic outcomes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Aim: The aim of this study is to investigate the clinicopathological characteristics and prognostic value of endometriosis in patients with ovarian cancer. Materials and Methods: A retrospective analysis was performed on 273 patients with ovarian carcinoma between January 2013 and December 2023. Patients were stratified into endometriosis-associated ovarian carcinoma (EAOC) and non-endometriosis-associated ovarian carcinoma (non-EAOC). Clinicopathological variables, including age, menopausal status, tumor size and volume, FIGO stage, histological subtype, serum tumor markers, and survival outcomes, were evaluated. Results: EAOC patients were significantly younger than non-EAOC patients (respectively 51 ± 11.4 years, 59 ± 11.2 years; p = 0.002). EAOC cases were more frequently diagnosed at FIGO stage I than non-EAOC cases (p = 0.001), whereas FIGO stage (III) disease was more prevalent in the non-EAOC group (p = 0.007). No significant differences were observed in CA-125 levels between groups. CA 19-9 levels were elevated in the EAOC group (p = 0.012). Recurrence rates and survival outcomes did not differ significantly between the groups. Conclusion: EAOC cases were diagnosed at a younger age and presented at an earlier FIGO stage and had elevated CA 19-9 levels. However, survival outcomes did not significantly differ between EAOC and non-EAOC groups.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (26)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK